Cargando…

The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD

Interstitial lung diseases (ILD) encompasses a heterogeneous group of parenchymal lung diseases characterized by variable amounts of inflammation and fibrosis. The targeting of fibroblasts and myofibroblasts with antifibrotic treatments is a potential therapeutic target for these potentially fatal d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kolb, Martin, Orfanos, Stylianos E., Lambers, Chris, Flaherty, Kevin, Masters, Alison, Lancaster, Lisa, Silverstein, Adam, Nathan, Steven D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402520/ https://www.ncbi.nlm.nih.gov/pubmed/35781186 http://dx.doi.org/10.1007/s12325-022-02229-8

Ejemplares similares

Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil
por: Chapman, Richard W., et al.
Publicado: (2021)

Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis
por: Nathan, Steven D, et al.
Publicado: (2022)

Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension
por: Raina, Amresh, et al.
Publicado: (2013)

Inhaled treprostinil: a therapeutic review
por: Channick, Richard N, et al.
Publicado: (2012)

Inhaled treprostinil and pulmonary arterial hypertension
por: Nadler, Samuel T, et al.
Publicado: (2010)

Effect of Inhalation Profile on Delivery of Treprostinil Palmitil Inhalation Powder
por: Gauani, Helena, et al.
Publicado: (2023)

Syndecan-2 regulates PAD2 to exert antifibrotic effects on RA-ILD fibroblasts
por: Tsoyi, Konstantin, et al.
Publicado: (2022)

Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD
por: Shumar, John N., et al.
Publicado: (2021)

Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension
por: Bourge, Robert C, et al.
Publicado: (2013)

Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)
por: Copeland, Carla R., et al.
Publicado: (2021)

Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension
por: Plaunt, Adam J., et al.
Publicado: (2021)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
por: Hill, Nicholas S., et al.
Publicado: (2022)

Inhaled Treprostinil after Initial Clinical Worsening: To Continue or Not to Continue, That’s the Question
por: Jin, Qi, et al.
Publicado: (2022)

Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension
por: Kuwana, Masataka, et al.
Publicado: (2023)

Orotracheal treprostinil administration attenuates bleomycin-induced lung injury, vascular remodeling, and fibrosis in mice
por: Nikitopoulou, Ioanna, et al.
Publicado: (2019)

Reply to Jin et al.: Inhaled Treprostinil after Initial Clinical Worsening: To Continue or Not to Continue, That’s the Question
por: Nathan, Steven D.
Publicado: (2022)

Treprostinil Reconstitutes Mitochondrial Organisation and Structure in Idiopathic Pulmonary Fibrosis Cells
por: Fang, Lei, et al.
Publicado: (2023)

A multicenter retrospective study of patients with pulmonary hypertension transitioned from inhaled to oral treprostinil
por: Zwicke, Diane L., et al.
Publicado: (2021)

Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications
por: Erre, Gian Luca, et al.
Publicado: (2021)

Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension
por: Swisher, John W., et al.
Publicado: (2016)

The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease
por: Bajwa, Abubakr A., et al.
Publicado: (2017)

Inhaled Treprostinil in Pulmonary Hypertension in the Context of Interstitial Lung Disease: A Success, Finally
por: Behr, Jürgen
Publicado: (2021)

Treprostinil for pulmonary hypertension
por: Skoro-Sajer, Nika, et al.
Publicado: (2008)

Mechanism of anti-remodelling action of treprostinil in human pulmonary arterial smooth muscle cells
por: Lambers, Christopher, et al.
Publicado: (2018)

Treprostinil inhibits proliferation and extracellular matrix deposition by fibroblasts through cAMP activation
por: Lambers, Christopher, et al.
Publicado: (2018)

Impact of inhaled treprostinil on risk stratification with noninvasive parameters: a post hoc analysis of the TRIUMPH and BEAT studies
por: Tonelli, Adriano R., et al.
Publicado: (2020)

Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study
por: Waxman, Aaron, et al.
Publicado: (2023)

Implementing the EXPEDITE parenteral induction protocol: Rapid parenteral treprostinil titration and transition to oral treprostinil
por: Kingrey, John F., et al.
Publicado: (2023)

Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension
por: Chen, Hubert, et al.
Publicado: (2013)

Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial
por: Nathan, Steven D., et al.
Publicado: (2021)

The PH‐ILD Detection tool: External validation and use in patients with ILD
por: Parikh, Raj, et al.
Publicado: (2023)

Real‐world use of inhaled treprostinil for lung disease‐pulmonary hypertension: A protocol for patient evaluation and prescribing
por: Johnson, Shelsey W., et al.
Publicado: (2022)

Tracking Validation of ILD
por: Lu, S.
Publicado: (2018)

ILD simulation model
por: Lu, S.
Publicado: (2018)

Liposomal Forms of Fluoroquinolones and Antifibrotics Decorated with Mannosylated Chitosan for Inhalation Drug Delivery
por: Le-Deygen, Irina, et al.
Publicado: (2023)

Inhaled treprostinil vs iloprost: Comparison of adherence, persistence, and health care resource utilization in patients with pulmonary arterial hypertension
por: Burger, Charles D, et al.
Publicado: (2023)

The design of the ILD forward region
por: Levy, A
Publicado: (2018)

(Selected) MDI Issues of ILD
por: Pöschl, Roman
Publicado: (2020)

Treprostinil stimulates the engraftment of haematopoetic stem cells
por: Hussain, Filza, et al.
Publicado: (2011)

Successful management of an inadvertent excessive treprostinil overdose
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_fff84pfho4tjqau4sl5jdf156c